Research Paper Volume 12, Issue 11 pp 10896—10911

SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway

Figure 2. SPTBN1 inhibits the growth of epithelial ovarian cancer cells in vitro and in vivo. (A, B) The protein level of SPTBN1 was detected by western blot. (C, D) The mRNA level of SPTBN1 was analyzed by real-time PCR. SPTBN1 was overexpressed in HO8910 cells but decreased in A2780 cells after transfection with the SPTBN1-V5 or SPTBN1-sh plasmid, respectively. *P < 0.05 vs Con-V5, **P < 0.01 vs Con-sh, n=3. (E, F) Cell viability was evaluated by CCK8 assay. **P < 0.01 vs Con-V5, *P < 0.05 vs Con-sh, n=3. (G) Cell proliferation was assessed by colony formation assay. Loss of SPTBN1 promotes the proliferation of A2780 and HO8910 cells. *P < 0.05 vs Con-sh, n=3; (HJ) Mouse xenograft tumors derived from A2780 cells. Loss of SPTBN1 promotes the growth of epithelial ovarian cancer cells in vivo. (H) Images of mice with tumors (upper) and harvested tumors for each treatment group (lower). (I) Tumor growth curves. (J) Tumor weight at sacrifice. *P < 0.05; **P < 0.01 vs LV-Con.